Long-term outcomes with frontline nilotinib versus imatinib in newly diagnosed chronic myeloid leukemia in chronic phase: ENESTnd 10-year analysis - Kantarjian, Hagop M.; Hughes, Timothy P.; Larson, Richard A.; Kim, Dong-Wook; Issaragrisil, Surapol; le Coutre, Philipp; Etienne, Gabriel; Boquimpani, Carla; Pasquini, Ricardo; Clark, Richard E.; Dubruille, Viviane; Flinn, Ian W.; et al. (Leukemia, 2021)
Keywords: 631/67/1990; 631/67/1990/283/1896; Adverse events; Antineoplastic Combined Chemotherapy Protocols - therapeutic use; Cancer Research; Chronic myeloid leukemia; Comparative analysis; Critical Care Medicine; Development and progression; Drug therapy; Evaluation; Female; Follow-Up Studies; Hematology; Humans; Imatinib; Imatinib Mesylate - administration & dosage; Inhibitor drugs; Intensive; Internal Medicine; Leukemia; Leukemia, Myelogenous, Chronic, BCR-ABL Positive - drug therapy; Leukemia, Myelogenous, Chronic, BCR-ABL Positive - mortality; Leukemia, Myelogenous, Chronic, BCR-ABL Positive - pathology; Male; Medicine; Medicine & Public Health; Middle Aged; Myeloid leukemia; Nilotinib; Oncology; Prognosis; Pyrimidines - administration & dosage; Remission; Risk assessment; Risk groups; Survival; Survival Rate; Targeted cancer therapy; United States